Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Molecular Testing Considerations for Patients With Pancreatic Cancer

Source: Global Perspective on BRCA Mutations, PARPi, and Biomarker-Driven Strategies in Pancreatic Cancer
Meet the global experts featured in this video and then review the latest data on clinically relevant alterations in BRCA1/2 and DNA damage repair genes, along with how and when to incorporate biomarker testing into management of pancreatic cancer.
Dirk Arnold, MD, PhD
Michael J. Pishvaian, MD, PhD
Released: October 8, 2020

This program is divided into several short segments which you can step through using the Video Chapters widget.
PreviousNext

Information on this Educational Activity

Faculty

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Dirk Arnold, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Pierre Fabre, and Roche; funds for research support from AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre; fees for non-CME/CE services from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pierre Fabre, and Roche; and other financial or material support from AstraZeneca.
Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Michael J. Pishvaian MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Caris, Celgene, Halozyme, Ipsen, MedImmune, Merck, Merrimack, Perthera, Rafael, RenovoRx, and Sirtex; has received funds for research support from Armo, AstraZeneca, Bavarian Nordic, Bayer, Boston Biomedical, Bristol-Myers Squibb, Calithera, Celgene, Celldex, Curegenix, FibroGen, Genentech, Gilead Sciences, GlaxoSmithKline, Halozyme, Karyopharm, MedImmune, Merck, Novartis, Pfizer, Pharmacyclics, Regeneron, and Tesaro; and has ownership interest in Perthera.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Target Audience

This program is intended for medical oncologists and other healthcare providers who care for patients with pancreatic cancer globally.

Goal

The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with pancreatic cancer.

Program Medium

This program has been made available online.

Related Content

From Clinical Care Options (CCO), downloadable PDF featuring key points from expert discussion on PARP inhibitors in treatment of pancreatic cancer

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: May 3, 2022

Video from Clinical Care Options (CCO): Expert insights on biomarker-driven treatment for gastrointestinal (GI) cancers

Pashtoon M. Kasi, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023

Expert commentary on biomarkers to guide therapy for patients with gastrointestinal cancers, from Clinical Care Options (CCO)

Christopher H. Lieu, MD Released: April 27, 2022

Clinical Care Options (CCO): Experts review key data for gastric, rectal, liver, hepatobiliary tract, and pancreas cancers from the 2022 ASCO Gastrointestinal Cancers Symposium and the ASCO Plenary Series

Manish A. Shah, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: April 20, 2022 Expired: April 19, 2023

Video Chapters

Molecular Testing Considerations for Patients With Pancreatic Cancer
BRCAm Pancreatic Therapy
Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings